National Taiwan University

Academia Sinica

Other

Taipei Medical University

Wo, Andrew Man, Chung

Bo-Tsang Huang

Pan-Chyr Yang

Konan Peck

Yi-Chung Chang

Wei-Yun Lai

Pei-Ying Lin

Shauh-Der Yeh

The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment

Aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity (e.g., promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV, or HCV infection.

Antagonistic PDL1 aptamers and their applications in cancer therapy

Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.

Antagonistic CTLA-4 aptamers and applications thereof in enhancing immune activity

Growing community of inventors

Taipei, Taiwan

Bo-Tsang Huang